Ranibizumab
- Generic Name
- Ranibizumab
- Brand Names
- Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 347396-82-1
- Unique Ingredient Identifier
- ZL1R02VT79
- Background
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...
- Indication
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...
- Associated Conditions
- Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth
- Conditions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 5
- Registration Number
- NCT00685854
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth
- Conditions
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Eye Institute (NEI)
- Target Recruit Count
- 1
- Registration Number
- NCT00685503
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
- First Posted Date
- 2008-05-21
- Last Posted Date
- 2012-11-08
- Lead Sponsor
- Reza Dana, MD
- Target Recruit Count
- 9
- Registration Number
- NCT00681889
- Locations
- 🇺🇸
Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment
- Conditions
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- Illinois Retina Associates
- Target Recruit Count
- 10
- Registration Number
- NCT00680498
- Locations
- 🇺🇸
Illinois Retina Associates, Oak Park, Illinois, United States
Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Johns Hopkins University
- Registration Number
- NCT00676559
- Locations
- 🇺🇸
Sharp Rees-Stealy Medical Group, San Diego, California, United States
🇺🇸Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸Eye Care Specialists, Kingston, Pennsylvania, United States
Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 61
- Registration Number
- NCT00674323
- Locations
- 🇹🇭
Novartis Investigative Site, Bangkok, Thailand
Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)
- Conditions
- Interventions
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Jumper, J. Michael, M.D.
- Target Recruit Count
- 6
- Registration Number
- NCT00668785
- Locations
- 🇺🇸
West Coast Retina Medical Group Inc., San Francisco, California, United States
Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- University of California, Irvine
- Registration Number
- NCT00667472
Use of Ranibizumab With Mitomycin C During Trabeculectomy
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 30
- Registration Number
- NCT00661583
- Locations
- 🇺🇸
Rocky Mountain Lions Eye Institute, Aurora, Colorado, United States
Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
- Conditions
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 11
- Registration Number
- NCT00657202
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.